The New England journal of medicineAdultAged80 and overFemaleHumans
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.
Pasi A Jänne, David Planchard, Kunihiko Kobayashi, James Chih-Hsin Yang, Ying Liu, Natalia Valdiviezo, Tae Min Kim, Liyan Jiang, Hiroshi Kagamu, Noriko Yanagitani, Jialei Wang, Bivas Biswas, Artem Poltoratskiy, Yeni Neron, Carlos Rojas
Published: 202610.1056/NEJMoa2510308
Abstract
BACKGROUND: The primary analysis of this trial showed that first-line treatment with osimertinib plus chemotherapy with a platinum-based agent and pemetrexed led to significantly longer progression-free survival than osimertinib monotherapy among pat…
Preview only. Read the full abstract at the source